Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | GPR27 | Q9NS67 | 2/20 | 0.36 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.36 |
| ▸ | CXCR5 | P32302 | 3/20 | 0.35 |
| ▸ | PGR | P06401 | 2/20 | 0.34 |
| ▸ | CCR2 | P41597 | 2/20 | 0.34 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.34 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.34 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.33 |
| ▸ | ACLY | P53396 | 2/20 | 0.33 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.33 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23877476 | 0.92 | TBXA2R (0.35) | KMT2AGPR27AVPR2CXCR5PGR | |
| SCHEMBL23877457 | 0.85 | DDR1 (0.38) | GPR27CXCR5SLC22A12TBXA2RDDR1 | |
| SCHEMBL23877608 | 0.81 | TNF (0.35) | GPR27CXCR5SLC22A12DDR1 | |
| SCHEMBL30547598 | 0.80 | KCNA5 (0.41) | ACLY | |
| SCHEMBL23877460 | 0.80 | KCNA5 (0.41) | ACLY | |
| SCHEMBL23877642 | 0.80 | ALDH1A1 (0.43) | KMT2AGPR27MCL1 | |
| SCHEMBL23877475 | 0.79 | USP2 (0.47) | GPR27AVPR2CCR2ACLY | |
| SCHEMBL31046899 | 0.79 | USP2 (0.47) | GPR27AVPR2CCR2ACLY | |
| SCHEMBL26188691 | 0.78 | KMT2A (0.36) | KMT2ACXCR5PGRNR1H4TBXA2R | |
| SCHEMBL23877445 | 0.78 | PDK1 (0.36) | CXCR5SLC22A12TBXA2RDDR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12606522-B2 | Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives | ORSOBIO, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| US-20240409508-A1 | SULFINYLAMINOBENZAMIDE AND SULFONYLAMINOBENZAMIDE DERIVATIVES | ORSOBIO, INC. | 2024-12-12 | — | — | US | disclosed |
| US-12049439-B2 | Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives | ORSOBIO, INC. (US) | 2024-07-30 | — | — | US | disclosed |
| EP-3796975-B1 | SULFONYLAMINOBENZAMIDE DERIVATIVES | ORSOBIO INC (US) | 2023-08-30 | — | — | EP | disclosed |
| EP-3796975-B1 | SULFONYLAMINOBENZAMIDE DERIVATIVES | ORSOBIO INC (US) | 2023-08-30 | — | — | EP | disclosed |
| US-20220055985-A1 | SULFINYLAMINOBENZAMIDE AND SULFONYLAMINOBENZAMIDE DERIVATIVES | GILEAD SCIENCES, INC. | 2022-02-24 | — | — | US | disclosed |
| US-20220055985-A1 | SULFINYLAMINOBENZAMIDE AND SULFONYLAMINOBENZAMIDE DERIVATIVES | GILEAD SCIENCES, INC. | 2022-02-24 | — | — | US | disclosed |
| US-11136290-B2 | Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives | THE LIVER COMPANY INC. (US) | 2021-10-05 | — | — | US | disclosed |
| US-11136290-B2 | Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives | THE LIVER COMPANY INC. (US) | 2021-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220055985-A1 | SULFINYLAMINOBENZAMIDE AND SULFONYLAMINOBENZAMIDE DERIVATIVES | STS, SULT2A1, SCN2B | KMT2A 1234/4885GPR27 2330/4885AVPR2 330/4885 |
| US-12049439-B2 | Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives | STS, SULT2A1, SCN2B | KMT2A 1234/4885GPR27 2330/4885AVPR2 330/4885 |
| US-12606522-B2 | Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives | NR3C2, NR5A1, SRD5A2 | KMT2A 2071/4885GPR27 742/4885AVPR2 923/4885 |
| US-20240409508-A1 | SULFINYLAMINOBENZAMIDE AND SULFONYLAMINOBENZAMIDE DERIVATIVES | STS, SULT2A1, SCN2B | KMT2A 1234/4885GPR27 2330/4885AVPR2 330/4885 |
| US-11136290-B2 | Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives | STS, SULT2A1, SCN2B | KMT2A 1234/4885GPR27 2330/4885AVPR2 330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.